Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia

Pearson marrow pancreas syndrome (PS) is a multisystem disorder caused by mitochondrial DNA (mtDNA) deletions. Diamond-Blackfan anemia (DBA) is a congenital hypoproliferative anemia in which mutations in ribosomal protein genes and GATA1 have been implicated. Both syndromes share several features in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2014-07, Vol.124 (3), p.437-440
Hauptverfasser: Gagne, Katelyn E., Ghazvinian, Roxanne, Yuan, Daniel, Zon, Rebecca L., Storm, Kelsie, Mazur-Popinska, Magdalena, Andolina, Laura, Bubala, Halina, Golebiowska, Sydonia, Higman, Meghan A., Kalwak, Krzysztof, Kurre, Peter, Matysiak, Michal, Niewiadomska, Edyta, Pels, Salley, Petruzzi, Mary Jane, Pobudejska-Pieniazek, Aneta, Szczepanski, Tomasz, Fleming, Mark D., Gazda, Hanna T., Agarwal, Suneet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pearson marrow pancreas syndrome (PS) is a multisystem disorder caused by mitochondrial DNA (mtDNA) deletions. Diamond-Blackfan anemia (DBA) is a congenital hypoproliferative anemia in which mutations in ribosomal protein genes and GATA1 have been implicated. Both syndromes share several features including early onset of severe anemia, variable nonhematologic manifestations, sporadic genetic occurrence, and occasional spontaneous hematologic improvement. Because of the overlapping features and relative rarity of PS, we hypothesized that some patients in whom the leading clinical diagnosis is DBA actually have PS. Here, we evaluated patient DNA samples submitted for DBA genetic studies and found that 8 (4.6%) of 173 genetically uncharacterized patients contained large mtDNA deletions. Only 2 (25%) of the patients had been diagnosed with PS on clinical grounds subsequent to sample submission. We conclude that PS can be overlooked, and that mtDNA deletion testing should be performed in the diagnostic evaluation of patients with congenital anemia. •PS can be overlooked in the differential diagnosis of children with severe congenital anemia.•mtDNA deletion testing should be included in the genetic evaluation of patients with congenital anemia of unclear etiology.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2014-01-545830